Clinical Trials Logo

Other clinical trials

View clinical trials related to Other.

Filter by:

NCT ID: NCT05332340 Completed - Prostate Cancer Clinical Trials

Safety, Tolerability and Pharmacokinetics (PK) Evaluation of BZ371A, Topically Administered

Start date: November 16, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate pharmacokinetics, safety and tolerability profile of BZ371A topically administered in healthy patients.

NCT ID: NCT05331833 Completed - Clinical trials for Stage III Non-small-cell Lung Cancer

Omitting Clinical Target Volume of Unresectable Stage III Non-small-cell Lung Cancer.

Start date: August 1, 2016
Phase:
Study type: Observational

About 20-30% of patients with stage III non-small cell lung cancer (NSCLC) are unresectable and definitive concurrent radiochemotherapy is the standard care. Intensity-modulated radiation therapy (IMRT) is a new radiotherapy technology, including gross tumor volume (GTV), clinical target volume (CTV), internal target volume (ITV), and planning target volume (PTV) as delineated target volumes. The treatment failure of local advanced NSCLC is mainly caused by local recurrence accounted for 50% and distant metastasis accounted for 50%. Local recurrence occurs both within the radiation field and outside the radiation field. Elective nodal irradiation (ENI) was designed before, however the adverse events (AEs) was not satisfactory. Afterwards, involved field radiotherapy (IFRT) showed that a reduced irradiation field did not increase local recurrence, and lowered the AEs Thus, IFRT has been broadly used in clinical work instead of ENI. IFRT still has disadvantages, including the risk of radiation respiratory events and radiation esophagitis, can the irradiation area be further reduced to reduce adverse reactions without affecting the efficacy? Positron emission tomography -computed tomography (PET-CT) can accurately assess primary tumor and metastatic lymph nodes in NSCLC patients better than CT . A meta-analysis of 39 clinical studies showed that the median sensitivity and specificity of PET-CT for the detection of lymph node involvement were 85% and 90%, respectively, while those of CT alone were only 61% and 79%, respectively. The radiotherapy application of PET-CT in image acquisition can ensure the delineation of both primary tumor and mediastinal lymph node metastasis. Under this condition, can the radiation field be further reduced to lower the dose to normal tissue and radiotherapy-associated AEs? A dosimetry study showed that when a dose of 60 Gy was given to the primary tumor and positive mediastinal lymph nodes, even if the CTV was omitted, a dose of 50 Gy was sufficient to cover the subclinical area.

NCT ID: NCT05331651 Completed - Clinical trials for Postoperative Nausea and Vomiting

Effect of Glycopyrronium in Combination With Tropisetron in Anti-postoperative Nausea and Vomiting

Start date: April 8, 2022
Phase: Phase 4
Study type: Interventional

To compare the anti-nausea and vomiting effect between glycopyrronium in combination with tropisetron and normal saline in combination with tropisetron for patients receiving elective surgery under general anesthesia. Based on this study the investigators intend to explore the feasibility of using glycopyrronium as adjuvant drug to prevent postoperative nausea and vomiting.

NCT ID: NCT05331287 Completed - Clinical trials for Therapeutic Procedural Complication

Comparing the "Snifing Position" , "Simple Head Extension" and "Neutral Position"

Start date: April 20, 2022
Phase: N/A
Study type: Interventional

The simple head extension is recommended for optimization of glottic visualization during Nasotracheal intubation via fiberoptic bronchoscope (FOB) . However, no study confirmed its superiority over"snifing position" and "Neutral Position". In a prospective, randomized study, the authors compared the snifing position , simple head extension and "Neutral Position" in Nasotracheal intubation via fiberoptic bronchoscope.

NCT ID: NCT05330260 Completed - Surgery Clinical Trials

Five Years Follow-up of Neurological Outcome After Minimally Invasive Cardiac Surgery

FUNOMICS
Start date: March 25, 2022
Phase:
Study type: Observational [Patient Registry]

A monocenter observational study will be started to investigate postoperative cognitive dysfunction 5 years after minimally invasive cardiac surgery. Postoperative cognitive dysfunction will be evaluated in three groups: an endoscopic-CABG group (endo-CABG), a PCI (Percutaneous Coronary Intervention) group and a healthy control group. It is hypothesized that the endo-CABG group will show a stronger postoperative cognitive dysfunction compared to the PCI group and the healthy control group.

NCT ID: NCT05329857 Completed - Clinical trials for To Determine Bioequivalence Under Fed Conditions

The Study Intends to Show Bioequivalence of the Test Product and the Reference Reference Product in a Crossover Design Study Healthy Volunteers. Additionally, the Safety Profile of Test Product Compared to Reference Product Will be Evaluated.

Start date: December 2015
Phase: N/A
Study type: Interventional

To evaluate and compare the relative bioavailability and therefore the bioequivalence of fixed dose combination of Metformin and Vildagliptin Tablets 1000/50 mg manufactured by Oman Pharmaceuticals Products Co. LLC, Sultanate of Oman, with EUCREAS® 50/1000 mg tablets manufactured by Novartis Pharma GmbH, Germany, in Normal, Healthy, Adult, Male Human Subjects under Fed Conditions.

NCT ID: NCT05328752 Completed - Clinical trials for Heart Failure With Reduced Ejection Fraction (HFrEF)

Safety and Tolerability Study of XXB750 in Heart Failure Participants With Reduced or Mildly Reduced Ejection Fraction (HFrEF/HFmrEF)

Start date: May 17, 2022
Phase: Phase 1
Study type: Interventional

This is a multi-center, randomized, sponsor open-label, participant- and investigator-blinded, placebo-controlled, single and multiple dose study to investigate the safety and tolerability of XXB750 in HFrEF/HFmrEF.

NCT ID: NCT05327374 Completed - COPD Exacerbation Clinical Trials

Use of ΔIVC for Early Diagnosis of AHF in AECOPD

Start date: March 1, 2022
Phase:
Study type: Observational

Acute Heart failure (AHF) is a common cause of acute exacerbation of chronic obstructive pulmonary disease (AECOPD). This association is frequently underestimated with regard to the difficulty of clinical diagnosis. The investigators expect that the application of the inferior vena cava collapsibility index (ΔIVC)could be useful in this issue.

NCT ID: NCT05326360 Completed - Clinical trials for Breast Cancer Female

Ramosetron on Late PONV (Postoperative Nausea and Vomiting)

Start date: December 17, 2020
Phase: Phase 4
Study type: Interventional

The purpose of this study was to evaluate the effectiveness of additional ramosetron injection for controlling late postoperative nausea and vomiting (PONV) after breast surgery in high risk PONV patients. The investigators compared PONV amomng 3 groups- group C: no additional ramosteron, group B: two additional ramosteron doses at 12 hour interval, group M: two additional ramosetron doses mix to the intraveonus patient controlled analgesia.

NCT ID: NCT05325775 Completed - Clinical trials for Post-menopausal Vasomotor Symptoms

Dose-ranging, PK, Safety, Efficacy Study of Osanetant in Patients With Moderate/Severe VMS Associated With Menopause

Start date: March 30, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

In this clinical research study, subjects will be given the study drug, ACER-801 (osanetant) or placebo (looks like the study drug but contains no active ingredients). The study drug works on a receptor in the brain and the intended purpose is for the study treatment of moderate to severe Vasomotor Symptoms (VMS) also referred to as hot flashes or flushes associated with menopause. Hot flashes are a change in your temperature that occurs due to changes in your hormones.